Advancing treatment options for cancer.

The Hsp90 chaperone proteins is an attractive oncology target with potential across multiple tumor types. Since the early 2000s, more than 20 molecules have been investigated in clinical trials, many of which were sponsored by major pharma companies. Unfortunately, to date none have received FDA approval, due to on-target toxicities and disappointing efficacy results. All these failed trials utilized pan inhibitors that targeted all four isoforms of Hsp90: alpha, beta, GRp94, and Trap-1.

Grannus has overcome the limitations and failures of previous Hsp90 inhibitors, through the breakthrough development of the first-in-class Hsp90𝛽-selective inhibitor. With clean toxicity profiles and demonstrated in-vivo efficacy, Grannus is poised to bring a new treatment option to patients in need across multiple solid tumors.